Interferon_beta-1a: profile and news

[an error occurred while processing this directive]

Other information

Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum

Pharmacology
Interferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Type I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin and neopterin.

Mechanism Of Action
Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.

Drug Category
Antiviral Agents; Immunomodulatory Agents; unclassified therapeutic agents (92:00.00)

Brand Names/Synonyms
Interferon beta precursor;IFN-beta;Fibroblast interferon; Avonex (Biogen Inc)

Dosage Forms
LIQUID

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Human interferon beta

Chemical Formula
C908H1408N246O252S7

Half Life
10 hrs

Drug Type
Approved Drug

# Accession No
BIOD00093

CAS Registry Number
145258-61-3